VI
Vir Biotechnology, Inc.
VIR · NASDAQ
$10.77 +0.33% (+$0.04)
1M +13.10%
Market Cap $1.82B
P/E Ratio -
Div. Yield -
ROE 29.99%
Bulios Fair Price
$7.82
27.4% downside
Current Price
$10.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VIR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
58 /100
Fair P/B 1.85x
P/S 5.99x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 28.32%
Rev. growth 65.12%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 88.97%
Gross margin 170.01%
FCF margin 109.34%
Quality
3 /100
Poor ROA 20.72%
ROIC 23.93%
Asset turnover 0.25x
Debt
100 /100
Low Current ratio 6.04x
Debt/Equity 0.09x
Debt/Assets N/A
Stability
7 /100
Unstable EPS volatility 136.76%
Beta 1.63x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VIR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Marianne De Backer
Employees
367
Headquarters
San Francisco
Upcoming events
04 NOV
Earnings
Upcoming earnings report